RENEW-SHCS: Safety and Immunogenicity of a Recombinant HIV Env Protein Vaccine in ARV-treated Adults Living With HIV in the SHCS

计划入组 30 人 · 首次发布于 2026 年 8 月 18 日

A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya

计划入组 143 人 · 首次发布于 2021 年 4 月 1 日

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

计划入组 1,512 人 · 首次发布于 2019 年 8 月 26 日

rVSVΔG-Env-HIV

VRC-HIVADV052-00-VP

rcAd26.MOS1.HIV-Env

Protein Sciences Corporation

United States

Worcester HIV Vaccine

United States

HIV VACCINE TRIALS NETWORK

United States

First-in-Human HIV Vaccine Induces Virus-Specific Neutralizing Antibodies

Weill Cornell Medicine Receives $20.8 Million NIH Grant to Develop Childhood HIV Vaccine

Uvax Bio's HIV-1 Vaccine Candidate Shows Promising Early Results in Phase 1 Trial